Trichomoniasis Medication

Updated: Jan 02, 2020
  • Author: Darvin Scott Smith, MD, MSc, DTM&H; Chief Editor: Michael Stuart Bronze, MD  more...
  • Print
Medication

Medication Summary

The following treatment options include:

  • Single-dose 2-g oral metronidazole, tinidazole, or secnidazole therapy
  • Prolonged metronidazole therapy with 500 mg twice daily for 7 days 

Single-dose nitroimidazole therapies are highly effective in the treatment of trichomoniasis. 

Drug-resistance in T vaginalis infection is rare, despite the prevalent use of nitroimidazole drugs. Treatment failures may require a higher-dose regimen, a longer course of the agent, or the use of different nitroimidazoles. In cases of resistance, nimorazole, ornidazole, furazolidone, ornidazole, and hamycin have been used with success. [117]

Consultation with CDC experts may be advisable for patients in whom treatment fails and in whom reinfection is ruled out (770-488-4115). Consultation with an infectious diseases specialist, a gynecologist, or both may be helpful.

Next:

Nitroimidazoles

Class Summary

Therapy must be comprehensive and should cover all likely pathogens in the context of the clinical setting. In the treatment of trichomoniasis, 5-nitroimidazole drugs are the only widely used antiprotozoal agents. [11] 5-Nitroimidazoles are believed to disrupt the helical structure of DNA in trichomonads, ultimately leading to cell death. [115] The exact mechanisms of many antiprotozoal agents, including 5-nitroimidazoles, are not well understood.

Metronidazole (Flagyl)

Metronidazole is highly effective in the treatment of many anaerobic bacterial and protozoal infections. Oral metronidazole is the drug of choice for trichomoniasis. Single-dose therapy with 2 g orally is as effective as prolonged therapy with 500 mg twice daily for 7 days. Single-dose therapy increases compliance. Cure rates of 90-95% for trichomoniasis have been reported with these recommended dosages. Treating the patient's sexual partners further improves the cure rate. Trichomonal resistance to this agent has also been reported; current resistance rates are reported at 5-10%.

If treatment with either single-dose or multidose therapy fails, a regimen of 2 g of oral metronidazole or tinidazole for 5 days may be considered. Metronidazole gel is not recommended for the treatment of trichomoniasis because therapeutic levels are not reached.

Patients should not consume alcohol during the course of treatment and for 24 hours after the last dose. The CDC currently recommends that infected symptomatic pregnant females be treated with 2 g metronidazole in a single dose. Infected asymptomatic pregnant women may wish to defer treatment to after 37 weeks' gestation.

The mode of action of metronidazole is not well understood. The drug appears to be absorbed into cells; intermediate metabolites bind DNA and inhibit protein synthesis, causing cell death.

Tinidazole (Tindamax)

Tinidazole has a longer half-life (12-14 h) than metronidazole (6-7 h). Therapy consists of a single oral 2-g dose taken with food. Reported cure rates for trichomoniasis range from 86-100%. Randomized clinical trials comparing single 2-g doses have shown metronidazole and tinidazole to be equally effective. The CDC has reported cases of metronidazole-resistant T vaginalis that was susceptible to tinidazole.

Patients on tinidazole therapy should not consume alcohol during therapy or for 72 hours after completion of the medication. Tinidazole is not recommended for the treatment of trichomoniasis in pregnant women.

Tinidazole is a 5-nitroimidazole derivative used for susceptible protozoal infections. The nitro group is reduced by a cell extract of Trichomonas. The free nitro radical generated is thought to be responsible for antiprotozoal activity against T vaginalis. The advantage of tinidazole over metronidazole is that it has fewer adverse effects, including nausea and vomiting, and may be better tolerated in a single high dose.

Secnidazole (Solosec)

Nitroimidazole derivative. Indicated for treatment of trichomoniasis caused by Trichomonas vaginalis in adults. In clinical a multicenter clinical trial, efficacy ranged from 92.2% to 100% compared with placebo, including women with HIV. 

Previous